Mon, Sep 21, 2020 – 8:19 AM
CATALIST-LISTED iX Biopharma has been granted a patent in Israel for its WaferiX drug supply expertise, it stated in a bourse submitting on Monday.
The patent, which expires on Oct 11, 2033, will present key mental property safety for the corporate’s WaferiX supply expertise platform within the nation, it added.
In its submitting, iX Biopharma additionally stated it had been issued a patent for WaferiX within the US, which is able to expire on Oct 26, 2030. This follows the corporate’s June 9 announcement that it had acquired a discover of allowance from the USA Patent and Trademark Workplace for the expertise.
With the Israel patent, the mental property rights for iX Biopharma’s sublingual wafer expertise is now secured in all key markets, together with the US, China, Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia and Indonesia, the pharmaceutical firm stated.
WaferiX is a a number of drug service platform expertise that permits pharmacologically energetic compounds, resembling ketamine and sildenafil, to be administered sublingually (positioned underneath the tongue) and delivered “safely, conveniently and quickly” into the bloodstream, it added.
Shares of iX Biopharma ended Friday flat at S$0.22.